CAR-T Cell Therapy in Ovarian Cancer: Where Are We Now?

Diagnostics, Journal Year: 2024, Volume and Issue: 14(8), P. 819 - 819

Published: April 16, 2024

The success of chimeric antigen receptor T-cell (CAR-T) therapies in the treatment hematologic malignancies has led to investigation their potential solid tumors, including ovarian cancer. While immunosuppressive microenvironment cancer been a barrier implementation, several early phase clinical trials are currently evaluating CAR-T cell targeting mesothelin, folate a, HER2, MUC16, and B7H3. Ongoing challenges include cytokine-associated “on-target, off-tumor” toxicities, while most common adverse events cytokine release syndrome, hemophagocytic lymphohistiocytosis/macrophage activation-like syndrome (HLH/MAS), neurotoxicity. In present review, we summarize current status therapy discuss future directions.

Language: Английский

---

From glioma gloom to immune bloom: unveiling novel immunotherapeutic paradigms-a review

Journal of Experimental & Clinical Cancer Research, Journal Year: 2024, Volume and Issue: 43(1)

Published: Feb. 12, 2024

Abstract In tumor therapeutics, the transition from conventional cytotoxic drugs to targeted molecular therapies, such as those targeting receptor tyrosine kinases, has been pivotal. Despite this progress, clinical outcomes have remained modest, with glioblastoma patients' median survival stagnating at less than 15 months. This underscores urgent need for more specialized treatment strategies. Our review delves into progression toward immunomodulation in glioma treatment. We dissect critical discoveries immunotherapy, spotlighting instrumental role of tumor-associated macrophages, which account approximately half immune cells microenvironment, and myeloid-derived suppressor cells. The complex interplay between microenvironment explored, revealing novel therapeutic targets. uniqueness our is its exhaustive approach, synthesizing current research elucidate intricate roles various molecules receptors within microenvironment. comprehensive synthesis not only maps landscape but also provides a blueprint refining immunotherapy glioma, signifying paradigm shift leveraging mechanisms improved patient prognosis.

Language: Английский

---

Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma

Cancers, Journal Year: 2024, Volume and Issue: 16(4), P. 827 - 827

Published: Feb. 18, 2024

Chemoimmunotherapy and cellular therapy are the mainstay of treatment relapsed/refractory (R/R) lymphomas. Development resistance commonly encountered toxicities these treatments limit their role in achieving desired response rates durable remissions. The Antibody–Drug Conjugate (ADC) is a novel class targeted that has demonstrated significant efficacy treating various cancers, including To date, three ADC agents have been approved for different lymphomas, marking advancement field. In this article, we aim to review concept ADCs application lymphoma treatment, provide an analysis currently agents, discuss ongoing advancements development.

Language: Английский

---

Single-cell transcriptional profiling of clear cell renal cell carcinoma reveals a tumor-associated endothelial tip cell phenotype

Communications Biology, Journal Year: 2024, Volume and Issue: 7(1)

Published: June 28, 2024

Clear cell renal carcinoma (ccRCC) is the most prevalent form of cancer, accounting for over 75% cases. The asymptomatic nature disease contributes to late-stage diagnoses and poor survival. Highly vascularized immune infiltrated microenvironment are prominent features ccRCC, yet interplay between vasculature cells, progression response therapy remains poorly understood. Using droplet-based single-cell RNA sequencing we profile 50,236 transcriptomes from paired tumor healthy adjacent kidney tissues. Our analysis reveals significant heterogeneity inter-patient variability microenvironment. Notably, discover a previously uncharacterized subpopulation associated with epithelial-mesenchymal transition. cell-cell communication multiple modes immunosuppressive interactions within microenvironment, including clinically relevant stromal cells cells. upregulation genes involved in these worse survival TCGA KIRC cohort. findings demonstrate role populations shaping ccRCC uncover that an angiogenic phenotype.

Language: Английский

---

CD70-Targeted Immuno-PET/CT Imaging of Clear Cell Renal Cell Carcinoma: A Translational Study

Journal of Nuclear Medicine, Journal Year: 2024, Volume and Issue: unknown, P. jnumed.124.268509 - jnumed.124.268509

Published: Nov. 7, 2024

The diagnosis and surveillance of clear cell renal carcinoma (ccRCC) remains a clinical challenge. high specific expression the cluster differentiation 70 (CD70) in ccRCC makes it potential diagnostic therapeutic target.

Language: Английский

---